A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma

Falk Roeder, Daniela Schulz-Ertner, Anna V Nikoghosyan, Peter E Huber, Lutz Edler, Gregor Habl, Robert Krempien, Susanne Oertel, Ladan Saleh-Ebrahimi, Frank W Hensley, Markus W Buechler, Juergen Debus, Moritz Koch, Juergen Weitz, Marc Bischof, Falk Roeder, Daniela Schulz-Ertner, Anna V Nikoghosyan, Peter E Huber, Lutz Edler, Gregor Habl, Robert Krempien, Susanne Oertel, Ladan Saleh-Ebrahimi, Frank W Hensley, Markus W Buechler, Juergen Debus, Moritz Koch, Juergen Weitz, Marc Bischof

Abstract

Background: Local control rates in patients with retroperitoneal soft tissue sarcoma (RSTS) remain disappointing even after gross total resection, mainly because wide margins are not achievable in the majority of patients. In contrast to extremity sarcoma, postoperative radiation therapy (RT) has shown limited efficacy due to its limitations in achievable dose and coverage. Although Intraoperative Radiation Therapy (IORT) has been introduced in some centers to overcome the dose limitations and resulted in increased outcome, local failure rates are still high even if considerable treatment related toxicity is accepted. As postoperative administration of RT has some general disadvantages, neoadjuvant approaches could offer benefits in terms of dose escalation, target coverage and reduction of toxicity, especially if highly conformal techniques like intensity-modulated radiation therapy (IMRT) are considered.

Methods/design: The trial is a prospective, one armed, single center phase I/II study investigating a combination of neoadjuvant dose-escalated IMRT (50-56 Gy) followed by surgery and IORT (10-12 Gy) in patients with at least marginally resectable RSTS. The primary objective is the local control rate after five years. Secondary endpoints are progression-free and overall survival, acute and late toxicity, surgical resectability and patterns of failure. The aim of accrual is 37 patients in the per-protocol population.

Discussion: The present study evaluates combined neoadjuvant dose-escalated IMRT followed by surgery and IORT concerning its value for improved local control without markedly increased toxicity.

Trial registration: NCT01566123.

Figures

Figure 1
Figure 1
Flow Chart of the Study. IMRT: Intensity-Modulated Radiation Therapy, IORT: Intraoperative Radiation Therapy, Fx: Fractions.

References

    1. Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. The role of multimodality therapy in soft tissue sarcomas. Ann Surg. 1991;214:328–336. doi: 10.1097/00000658-199109000-00015.
    1. Catton CN, OSullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1994;29:1005–1010. doi: 10.1016/0360-3016(94)90395-6.
    1. Petersen IA, Haddock MG, Donohue JH, Nagorney DM, Grill J, Sargent DJ, Gunderson LL. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2002;52:469–475. doi: 10.1016/S0360-3016(01)02595-0.
    1. Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, Leung D, Brennan MF. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol. 1997;15:2832–2839.
    1. Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M, Rosai J. Retroperitoneal soft tissue sarcomas. Patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004;100:2448–2455. doi: 10.1002/cncr.20269.
    1. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228:355–365. doi: 10.1097/00000658-199809000-00008.
    1. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, Nguyen Bui B. French Federation of Cancer Centers Sarcoma Group. Prognostic factors in retroperitoneal sarcoma: A multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92:359–368. doi: 10.1002/1097-0142(20010715)92:2<359::AID-CNCR1331>;2-Y.
    1. Pisters PWT, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long term results of a prospective randomized trial evaluating the role of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–868.
    1. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft-tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203.
    1. Krempien R, Roeder F, Oertel S, Weitz J, Hensley FW, Timke C, Funk A, Lindel K, Harms W, Buchler MW, Debus J, Treiber M. Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int J Radiat Biol Oncol Phys. 2006;65:773–779. doi: 10.1016/j.ijrobp.2006.01.028.
    1. Tepper JE, Suit HD, Wood WC, Proppe KH, Harmon D, McNulty P. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1984;10:825–830. doi: 10.1016/0360-3016(84)90383-3.
    1. Fein DA, Corn BW, Lanciano RM, Herbert SH, Hoffman JP, Coia LR. Management of retroperitoneal sarcomas: Does dose escalation impact on locoregional control ? Int J Radiat Oncol Biol Phys. 1995;31:129–134. doi: 10.1016/0360-3016(94)E0302-Z.
    1. Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, Glatstein E. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized clinical trial. Arch Surg. 1993;128:402–410. doi: 10.1001/archsurg.1993.01420160040005.
    1. Gieschen HL, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Ancukiewicz M, Wilett CG. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50:127–131. doi: 10.1016/S0360-3016(00)01589-3.
    1. Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47:157–163. doi: 10.1016/S0360-3016(99)00546-5.
    1. Shaw EG, Gunderson LL, Martin JK, Beart RW, Nagorney DM, Podratz KC. Peripheral nerve and ureteral tolerance to intraoperative radiation therapy: Clinical and dose–response analysis. Radiother Oncol. 1990;18:247–255. doi: 10.1016/0167-8140(90)90060-A.
    1. Musat E, Kantor G, Caron J, Lagarde P, Laharie H, Stoeckle E, Angles J, Gilbeau L, Bui BN. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative conformal radiotherapy for retroperitoneal sarcoma. Cancer Radiother. 2004;8:255–261. doi: 10.1016/j.canrad.2004.05.001.
    1. Lohr F, Dobler B, Mai S, Hermann B, Tiefenbacher U, Wieland P, Steil V, Wenz F. Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol. 2003;179:557–563. doi: 10.1007/s00066-003-1087-z.
    1. Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys. 2000;48:1371–1380. doi: 10.1016/S0360-3016(00)00772-0.
    1. Lohr F, Debus J, Frank C, Herfarth K, Pastyr O, Rhein B, Bahner ML, Schlegel W, Wannenmacher M. Noninvasive patient fixation for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999;45:521–527. doi: 10.1016/S0360-3016(99)00190-X.
    1. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122.
    1. Chow SC, Shao J, Wang H. Sample sizes in clinical research. Marcel Dekker Inc, New York; 2003.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10. doi: 10.1016/0197-2456(89)90015-9.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅